Effect of API 0134 on platelet membrane glycoprotein expression in patients with hyperlipemia.
- Author:
Hong-wei WANG
1
;
Shu-sheng LI
;
Guo-ping WANG
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Andrographis; chemistry; Drugs, Chinese Herbal; pharmacology; therapeutic use; Female; Humans; Hyperlipidemias; blood; drug therapy; Male; Middle Aged; P-Selectin; blood; Phytotherapy; Platelet Glycoprotein GPIIb-IIIa Complex; metabolism; von Willebrand Factor; metabolism
- From: Chinese Journal of Integrated Traditional and Western Medicine 2004;24(5):389-391
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVEBy observing the effect of API 0134, an active ingredient of green chiretta, on platelet membrane glycoprotein (GP) in patients with hyperlipemia to explore the mechanism of the anti-platelet aggregation effect of API.
METHODSThe mean immunofluorescent intensity (MFI) of the platelet membrane glycoprotein GP II b/III a, GPIb, P-selectin (GMP-140) and von Willebrand's factor (vWF) in resting platelet, activated platelet (untreated or treated with API 0134 of different concentrations) were detected in 30 randomly selected patients with hyperlipemia, using immunofluorescent marker and flow cytometry.
RESULTSAPI of all concentrations (25 mg/L, 50 mg/L and 100 mg/L) could significantly decrease the MFI of GP II b/III a in a positive dose-dependent manner, as compared with that in activated platelet untreated with API; API of 50 mg/L and 100 mg/L could also reduce the MFI of GMP-140 and vWF in activated platelet (P < 0.01); but API of 100 mg/L showed insignificant influence on GPIb expression in activated platelet membrane.
CONCLUSIONAPI 0134 exerts obvious anti-platelet GP II b/III a effect on activated platelets, middle or large dose of API also shows inhibiting effect on GMP-140 and vWF expression in platelet.